Enveric Biosciences Stock Today

ENVB Stock  USD 1.73  0.04  2.37%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Enveric Biosciences is trading at 1.73 as of the 20th of March 2025, a 2.37 percent increase since the beginning of the trading day. The stock's open price was 1.69. Enveric Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of June 2015
Category
Healthcare
Classification
Health Care
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Enveric Biosciences, Inc. is headquartered in Naples, Florida. Enveric Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.92 M outstanding shares of which 274.69 K shares are currently shorted by private and institutional investors with about 0.6 trading days to cover. More on Enveric Biosciences

Moving together with Enveric Stock

  0.92EYEN EyenoviaPairCorr
  0.67MOLN Molecular PartnersPairCorr

Moving against Enveric Stock

  0.92FNA Paragon 28PairCorr
  0.85CPIX Cumberland PharmaceuticalsPairCorr
  0.64CMRX Chimerix Sell-off TrendPairCorr
  0.53OPT OptheaPairCorr

Enveric Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
Enveric Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enveric Biosciences' financial leverage. It provides some insight into what part of Enveric Biosciences' total assets is financed by creditors.
Liquidity
Enveric Biosciences currently holds 2.34 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Enveric Biosciences has a current ratio of 8.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Enveric Biosciences' use of debt, we should always consider it together with its cash and equity.

Change To Inventory

(190,391)
Enveric Biosciences (ENVB) is traded on NASDAQ Exchange in USA. It is located in 4851 Tamiami Trail N, Naples, FL, United States, 34103 and employs 7 people. Enveric Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.5 M. Enveric Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.92 M outstanding shares of which 274.69 K shares are currently shorted by private and institutional investors with about 0.6 trading days to cover. Enveric Biosciences currently holds about 18.01 M in cash with (14.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Enveric Biosciences Probability Of Bankruptcy
Ownership Allocation
Roughly 92.78 percent of Enveric Biosciences outstanding shares are held by general public with 0.06 (percent) owned by insiders and only 7.16 % by other corporate entities.
Check Enveric Ownership Details

Enveric Stock Institutional Holders

InstituionRecorded OnShares
Bank Of America Corp2024-09-30
173
Nelson, Van Denburg & Campbell Wealth Management Group, Llc2024-12-31
50.0
Wells Fargo & Co2024-09-30
16.0
Northern Trust Investments N A2024-12-31
0.0
Fmr Inc2024-09-30
0.0
Org Partners Llc2024-09-30
0.0
Mather Group, Inc.2024-09-30
0.0
Vanguard Group Inc2024-12-31
0.0
Hrt Financial Llc2024-09-30
0.0
Advisorshares Investments, Llc2024-09-30
367 K
Geode Capital Management, Llc2024-09-30
217.9 K
View Enveric Biosciences Diagnostics

Enveric Biosciences Historical Income Statement

At present, Enveric Biosciences' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 19.4 M, whereas Interest Expense is forecasted to decline to 3,170. View More Fundamentals

Enveric Stock Against Markets

Enveric Biosciences Corporate Management

Joseph TuckerCEO DirectorProfile
Ibrahim MDChief OfficerProfile
MBA IVInterim OfficerProfile
Peter FacchiniChief OfficerProfile
Avani KanubaddiPres COOProfile
Kevin CPAChief OfficerProfile
When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(34.31)
Revenue Per Share
37.678
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.97)
Return On Equity
(3.09)
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.